

STATUS OF CLAIMS

- 23. (cancelled)
- 24. (amended) A method of decreasing phagocytosis or ICAM-1 expression in a mammalian cell in need thereof, comprising contacting the cell with a therapeutically phagocytosis- or ICAM-1 decreasing effective amount of soybean milk containing soybean trypsin inhibitor that specifically decreases phagocytosis or ICAM-1 expression.
- 25. (cancelled)
- 28. (original) The method of claim 24, wherein the agent inhibits the PAR-2 pathway.
- 29. (original) The method of claim 24, wherein the agent is selected from the group consisting of a soybean derivative and a serine protease inhibitor.
- 30. (amended) The method of claim 29, wherein the agent is selected from the group consisting of soybean milk containing soybean trypsin inhibitor.
- 31. (original) The method of claim 23 or 24, wherein the mammalian cell is a PAR-2-expressing cell.
- 32. (original) The method of claim 31, wherein the mammalian cell is selected from the group consisting of a keratinocyte, a fibroblast, and a professional phagocyte.
- 33. (original) The method of claim 32, wherein the mammalian cell is a keratinocyte.
- 34. (original) The method of claim 32, wherein the mammalian cell is a fibroblast.
- 35. (original) The method of claim 32, wherein the mammalian cell is a professional phagocyte.
- 36. (original) The method of claim 23 or 24, wherein the mammalian cell is a human cell.
- 37. (cancelled)

38. (amended) A method of treating a mammal afflicted with a disorder ameliorated by a decrease in phagocytosis or ICAM-1 expression in appropriate cells, which comprises topically administered to the cells in need thereof a phagocytosis- or ICAM-1-decreasing therapeutically effective amount of soybean milk containing soybean trypsin inhibitor that specifically decreases phagocytosis or ICAM-1 expression.

39. (cancelled)

40. (amended) A method of preventing a mammal afflicted with a disorder ameliorated by a decrease in phagocytosis or ICAM-1 expression in appropriate cells, which comprises topically administering to the cells in need thereof a prophylactically phagocytosis- or ICAM-1 decreasing effective amount of soybean milk containing soybean trypsin inhibitor that specifically decreases phagocytosis or ICAM-1 expression.

41. (cancelled)

44. (original) The method of claim 38 or 40, wherein the agent inhibits the PAR-2 pathway.

45. (amended) The method of claim 38 or 40, wherein the agent is selected from the group consisting of soybean milk containing soybean trypsin inhibitor.

46. (amended) The method of claim 45, wherein the agent is selected from the group consisting of soybean milk containing soybean trypsin inhibitor.

47. (original) The method of claim 37, 38, 39 or 40, wherein the appropriate cells are PAR-2-expressing cells.

48. (cancelled)

49. (cancelled)

50. (cancelled)

51. (cancelled)
52. (cancelled)
53. (cancelled)
54. (cancelled)
55. (cancelled)
56. (cancelled)
57. (cancelled)
58. (original) The method of claim 37, 38, 39 or 40, wherein the mammal is a human.
59. (new) A method of decreasing phagocytosis or ICAM-1 expression in a mammalian cell in need thereof, comprising contacting the cell with a therapeutically phagocytosis- or ICAM-1 decreasing effective amount of a composition consisting essentially of soybean milk containing soybean trypsin inhibitor that specifically decreases phagocytosis or ICAM-1 expression.
60. (new) The method of claim 59, wherein the composition inhibits the PAR-2 pathway.
61. (new) The method of claim 59, wherein the mammalian cell is a PAR-2-expressing cell.
62. (new) The method of claim 61, wherein the mammalian cell is selected from the group consisting of a keratinocyte, a fibroblast, and a professional phagocyte.
63. (new) The method of claim 62, wherein the mammalian cell is a keratinocyte.
64. (new) The method of claim 62, wherein the mammalian cell is a fibroblast.
65. (new) The method of claim 62, wherein the mammalian cell is a professional phagocyte.
66. (new) The method of claim 59, wherein the mammalian cell is a human cell.